| Trial ID: | L6276 |
| Source ID: | NCT01867307
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01867307/results
|
| Conditions: |
Diabetes Mellitus, Type 2|Healthy
|
| Interventions: |
DRUG: Empagliflozin|DRUG: BI 10773
|
| Outcome Measures: |
Primary: Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14), Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Day 14). Per-protocol set (PPS): PPS consisted of all subjects and patients in the TS who completed the treatment day 14 clamping study without any relevant deviations either in their treatment regimen or in the performance and timing of the measurements., Baseline and Day 14 |
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-06
|
| Completion Date: |
2015-10
|
| Results First Posted: |
2017-05-11
|
| Last Update Posted: |
2017-05-11
|
| Locations: |
Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01867307
|
